ES2172744T3 - Composiciones farmaceuticas que comprenden mirtazapina y uno o varios inhibidores selectivos de asimilacion de serotonina. - Google Patents

Composiciones farmaceuticas que comprenden mirtazapina y uno o varios inhibidores selectivos de asimilacion de serotonina.

Info

Publication number
ES2172744T3
ES2172744T3 ES97201853T ES97201853T ES2172744T3 ES 2172744 T3 ES2172744 T3 ES 2172744T3 ES 97201853 T ES97201853 T ES 97201853T ES 97201853 T ES97201853 T ES 97201853T ES 2172744 T3 ES2172744 T3 ES 2172744T3
Authority
ES
Spain
Prior art keywords
assimilation
serotonin
pharmaceutical compositions
selective inhibitors
ssri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97201853T
Other languages
English (en)
Spanish (es)
Inventor
Victor Johannes Nickolson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2172744(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2172744T3 publication Critical patent/ES2172744T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES97201853T 1996-06-19 1997-06-17 Composiciones farmaceuticas que comprenden mirtazapina y uno o varios inhibidores selectivos de asimilacion de serotonina. Expired - Lifetime ES2172744T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201703 1996-06-19

Publications (1)

Publication Number Publication Date
ES2172744T3 true ES2172744T3 (es) 2002-10-01

Family

ID=8224094

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97201853T Expired - Lifetime ES2172744T3 (es) 1996-06-19 1997-06-17 Composiciones farmaceuticas que comprenden mirtazapina y uno o varios inhibidores selectivos de asimilacion de serotonina.

Country Status (24)

Country Link
US (1) US5977099A (https=)
JP (2) JP4925074B2 (https=)
KR (1) KR100481254B1 (https=)
CN (1) CN1132581C (https=)
AR (1) AR007609A1 (https=)
AT (1) ATE213159T1 (https=)
AU (1) AU727851B2 (https=)
BR (1) BR9703624A (https=)
CA (1) CA2208199C (https=)
CZ (1) CZ290691B6 (https=)
DE (1) DE69710390T2 (https=)
DK (1) DK0813873T3 (https=)
ES (1) ES2172744T3 (https=)
HU (1) HU225534B1 (https=)
ID (1) ID17051A (https=)
IL (1) IL121076A (https=)
NO (1) NO313177B1 (https=)
NZ (1) NZ328113A (https=)
PL (1) PL188520B1 (https=)
PT (1) PT813873E (https=)
RU (1) RU2181287C2 (https=)
SG (1) SG60073A1 (https=)
TR (1) TR199700522A3 (https=)
ZA (1) ZA975335B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
JP2001522891A (ja) * 1997-11-14 2001-11-20 アクゾ・ノベル・エヌ・ベー 睡眠時無呼吸を治療するためのミルタザピンの使用
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
US6575147B2 (en) * 1999-02-25 2003-06-10 Go-Tec Internal combustion system adapted for use of a dual fuel composition including acetylene
AU781221B2 (en) * 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
AU780817B2 (en) * 2000-01-19 2005-04-21 Akzo Nobel N.V. Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
BR0108261A (pt) * 2000-02-11 2003-03-05 Akzo Nobel Nv Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
AU2002212888A1 (en) * 2000-11-01 2002-05-15 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
DE60224078T2 (de) * 2001-02-12 2008-12-04 N.V. Organon Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind.
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
EP1490073A4 (en) * 2002-03-21 2006-02-01 Martin C Hinz SEGMENT OPTIMIZATION TECHNOLOGY FOR THE SEROTONIN AND CATECHOLAMINE SYSTEM
AU2003274608A1 (en) * 2002-11-07 2004-06-07 Sunil Sadanand Nadkarni Process for preparation of polymorphic form of sertraline hydrochloride
KR100842694B1 (ko) * 2002-12-27 2008-07-01 오쓰까 세이야꾸 가부시키가이샤 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
MXPA05008943A (es) * 2003-02-21 2005-11-08 C Hinz Martin Tecnologia de optimizacion del segmento de sistema de serotonina y catecolamina.
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
WO2005023767A2 (en) 2003-09-10 2005-03-17 Brentwood Equities Ltd. Diastereomers of 4-aryloxy-3-hydroxypiperidines
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
RU2283097C2 (ru) * 2004-11-16 2006-09-10 Эльвира Ивановна Белобородова Способ лечения бронхиальной астмы, сочетанной с эрозивно-язвенными поражениями гастродуоденальной зоны
EP1827450A4 (en) * 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
EP2292269A3 (en) * 2004-11-19 2011-08-10 N.V. Organon Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
TWI609702B (zh) 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
CN101332193B (zh) * 2007-06-29 2012-12-12 杭州民生药业有限公司 一种马来酸氟伏沙明药物组合物的制备方法
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
KR101360698B1 (ko) 2009-06-09 2014-02-07 스미도모쥬기가이고교 가부시키가이샤 하이브리드식 쇼벨 및 그 제어방법
US8785453B2 (en) * 2009-11-13 2014-07-22 Green Cross Corporation Arylpiperazine-containing purine derivatives and uses thereof
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
CN102000334B (zh) * 2010-10-15 2012-02-22 北京大学 用于治疗抑郁症的复方制剂
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
TWI636784B (zh) * 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
AU8770282A (en) * 1981-08-27 1983-03-03 Shaun R. Coughlin Composition for the treatment of atherosclerosis
US4940585A (en) * 1989-02-17 1990-07-10 Hapworth William E Method for the treatment of nicotine withdrawal syndrome
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
DK0431663T3 (da) * 1989-12-06 1994-03-07 Akzo Nobel Nv Stabiliserende opløsninger af psykotrope midler
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
JP2001518520A (ja) * 1997-10-03 2001-10-16 キャリー メディカル コーポレイション ニコチンレセプターアンタゴニストおよび抗抑うつ薬または抗不安薬を含有するニコチン嗜癖を治療する組成物

Also Published As

Publication number Publication date
CZ290691B6 (cs) 2002-09-11
ID17051A (id) 1997-12-04
DE69710390T2 (de) 2002-08-14
CN1173330A (zh) 1998-02-18
HUP9701068A3 (en) 2000-07-28
JP2009137970A (ja) 2009-06-25
DK0813873T3 (da) 2002-05-27
CA2208199C (en) 2006-10-24
NO313177B1 (no) 2002-08-26
DE69710390D1 (de) 2002-03-21
TR199700522A2 (xx) 1998-01-21
IL121076A (en) 2000-10-31
BR9703624A (pt) 1998-09-01
ATE213159T1 (de) 2002-02-15
HK1006081A1 (en) 1999-02-12
CZ187097A3 (cs) 1998-01-14
TR199700522A3 (tr) 1998-01-21
PT813873E (pt) 2002-06-28
PL320628A1 (en) 1997-12-22
NZ328113A (en) 1999-09-29
HU9701068D0 (en) 1997-08-28
CA2208199A1 (en) 1997-12-19
HU225534B1 (en) 2007-02-28
IL121076A0 (en) 1997-11-20
NO972816L (no) 1997-12-22
ZA975335B (en) 1998-01-26
CN1132581C (zh) 2003-12-31
JPH1067663A (ja) 1998-03-10
RU2181287C2 (ru) 2002-04-20
MX9704579A (es) 1998-07-31
HUP9701068A2 (hu) 1998-08-28
AU2612997A (en) 1998-01-08
KR980000447A (ko) 1998-03-30
AU727851B2 (en) 2001-01-04
JP4925074B2 (ja) 2012-04-25
KR100481254B1 (ko) 2005-09-12
PL188520B1 (pl) 2005-02-28
US5977099A (en) 1999-11-02
AR007609A1 (es) 1999-11-10
SG60073A1 (en) 1999-02-22
NO972816D0 (no) 1997-06-18

Similar Documents

Publication Publication Date Title
ES2172744T3 (es) Composiciones farmaceuticas que comprenden mirtazapina y uno o varios inhibidores selectivos de asimilacion de serotonina.
AR008782A1 (es) Una composicion farmaceutica antitrombotica y antiaterogena, y sus usos
CO5251409A1 (es) Combinacion de un inhibidor de la recaptacion de seretonina e irandalona
JP2005532372A5 (https=)
CO4900058A1 (es) Terapia de combinacion para el tratamiento de psicosis
CO4410317A1 (es) Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos.
NO20014485D0 (no) Nye forbindelser og sammensetninger som proteaseinhibitorer
NO20045429L (no) Kombinasjon av organiske forbindelser
JPH1067663A5 (https=)
BR9714310A (pt) Composição farmacêutica
RU97110083A (ru) Комбинация, фармацевтическая композиция, способ лечения, использование и упаковка
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
RU2009113038A (ru) Комбинированная лекарственная терапия для лечения ожирения
AR023129A1 (es) Composiciones para mejorar la fertilidad
ES2160640T3 (es) Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos.
BR9813651A (pt) Compostos antipicornavirais e métodos para o seu uso e preparação
DK1370260T3 (da) Azoler, som malonyl-coa-decarboxylaseinhibitorer anvendelige som mataboliske modulatorer
ATE409065T1 (de) Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
AR038143A1 (es) Agonistas del receptor 2 del factor liberador de la corticotropina
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
NO20032371L (no) Makrolidsolvater
ES2183492T3 (es) Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
EA200200948A1 (ru) Лечение псориаза
SE9804126D0 (sv) New pharmaceutical composition
UA41350C2 (uk) Похідна морфоліну або її фармацевтично прийнятна сіль та фармацевтична композиція на її основі

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 813873

Country of ref document: ES